The Role of TAK1 in RANKL-Induced Osteoclastogenesis

• Published in: Calcified tissue international 2022-07, Vol.111 (1), p.1-12
• Main Authors: Jianwei, Wu, Ye, Tian, Hongwei, Wang, Dachuan, Li, Fei, Zou, Jianyuan, Jiang, Hongli, Wang
• Format: Article
• Language: English
• Subjects: Biochemistry; Biomedical and Life Sciences; Bone remodeling; Bone resorption; Bone turnover; Cell Biology; Cell survival; Endocrinology; Homeostasis; Intracellular signalling; Kinases; Life Sciences; MAP kinase; NF-κB protein; Orthopedics; Osteoclastogenesis; Osteoclasts; Osteolysis; Osteoporosis; Protein kinase; Review Article; Signal transduction; TAK1 protein; TRANCE protein
• ISSN: 1432-0827; 0171-967X; 1432-0827
• DOI: 10.1007/s00223-022-00967-z

Bone remodelling is generally a dynamic process orchestrated by bone-resorbing osteoclasts and bone-forming osteoblasts. Osteoclasts are the only cell type capable of bone resorption to maintain bone homeostasis in the human body. However, excessive osteoclastogenesis can lead to osteolytic diseases. The receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) has been widely considered to be an important modulator of osteoclastogenesis thereby participating in the pathogenesis of osteolytic diseases. Transforming growth factor β-activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, is an important intracellular molecule that regulates multiple signalling pathways, such as NF-κB and mitogen-activated protein kinase to mediate multiple physiological processes, including cell survival, inflammation, and tumourigenesis. Furthermore, increasing evidence has demonstrated that TAK1 is intimately involved in RANKL-induced osteoclastogenesis. Moreover, several detailed mechanisms by which TAK1 regulates RANKL-induced osteoclastogenesis have been clarified, and some potential approaches targeting TAK1 for the treatment of osteolytic diseases have emerged. In this review, we discuss how TAK1 functions in RANKL-mediated signalling pathways and highlight the significant role of TAK1 in RANKL-induced osteoclastogenesis. In addition, we discuss the potential clinical implications of TAK1 inhibitors for the treatment of osteolytic diseases.